Related Experiment Videos
Immunologic aspects of human proinsulin therapy
S E Fineberg1, M J Rathbun, S Hufferd
1Indiana University School of Medicine, Indianapolis.
Diabetes
|March 1, 1988
Summary
Human proinsulin (HPI) showed weak immunogenicity as a primary insulin treatment for diabetes. Patients treated with HPI required less additional regular human insulin (HI) and developed fewer anti-HI antibodies.
Area of Science:
- Endocrinology
- Immunology
- Metabolic Diseases
Background:
- Insulin therapy is crucial for managing diabetes mellitus.
- Understanding the immunogenicity of different insulin formulations is vital for optimizing treatment.
- Human proinsulin (HPI) has been explored as a potential insulin agonist.
Purpose of the Study:
- To investigate the immunogenicity of human proinsulin (HPI) as a sole or principal insulin agonist.
- To compare the efficacy and antibody formation between HPI and recombinant DNA human insulin (HI) in insulin-naive patients with type I and type II diabetes.
Main Methods:
- A clinical study involving 61 patients treated with rDNA human insulin (HI) and 53 patients treated with HPI.
- Assessment of glycemic control (HbA1c) and antibody binding levels at 6 months.
- Analysis of the need for additional regular human insulin therapy.
Main Results:
- Virtually identical HbA1c levels were achieved in both HPI and HI groups (5.2% vs. 5.3%).
- HPI-treated patients required significantly less concomitant regular HI (16 vs. 32 patients, P < .001).
- HPI demonstrated weak immunogenicity, with low levels of HPI binding in a small subset of patients and a reduced prevalence of anti-HI antibodies compared to the HI group (20/51 vs. 39/60, P = .008).
Conclusions:
- Human proinsulin is a weak immunogen when used as the principal insulin agonist.
- HPI may reduce the formation of anti-HI antibodies.
- HPI therapy may decrease the need for concomitant regular HI, potentially simplifying diabetes management.